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1. INTRODUCTION 
The   hemodynamic   responses   to   laryngoscopy   and   
endotracheal intubation have been recognized since 1951. Though these 
pressor responses have been observed frequently they have been 
interpreted differently by many authors. The induction of anaesthesia, 
laryngoscopy, endotracheal intubation and surgical stimulation often 
evoke cardiovascular responses characterized by alterations in systemic 
blood pressure, heart rate and cardiac rhythm. The response following 
laryngoscopy and intubation peaks at 1-2 min and returns to baseline 
within 5-10 mins. 
These sympathoadrenergic responses are probably of little clinical 
consequence in healthy patients. Complications like myocardial 
ischemia, left ventricular failure, and cerebral haemorrhage have been 
attributed to sudden rise in systemic arterial blood pressure and increase 
in heart rate.   These complications   are   more   likely   to   occur   in   
patients   with   pre   existing hypertension, coronary heart disease, 
cerebral vascular disease, intracranial pathology and hyperactive airways. 
In such cases, reflex circulatory responses such as increase in heart rate, 
systemic arterial blood pressure and disturbances in cardiac rhythm need 
to be suppressed. 
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Prof. Ward and King(1) in their combined study documented 
myocardial   ischemic   changes   due   to   reflex   sympathoadrenal   
response immediately following laryngoscopy and endotracheal 
intubation with a mean increase in systemic pressure of 40mmHg even in 
normotensive patients. 
Prys Roberts et al(2)  showed an exaggerated form of this 
response in hypertensive patients. Anti hypertensive drugs modify the 
response but do not inhibit it completely. 
The cardiovascular responses during laryngoscopy and 
endotracheal intubation should be abolished to balance the myocardial 
oxygen supply and demand which is a key note in the safe conduct of 
Anaesthesia. 
Attempts to reduce these untoward haemodynamic responses 
during laryngoscopy and endotracheal intubation lead to the trial of 
various systemic as well as topical agents. 
The present concept of a definitive sympathetic overactivity during 
laryngeal intubation clearly shows that a more protection against vagal 
overactivity and the use of anticholinergic drugs alone may not be 
sufficient. Those techniques which require prior laryngoscopy to 
administer the local anaesthetic solution are likely to be of limited value.  
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The common strategies adapted are narcotics, vasodilators, Beta blockers, 
calcium channel blockers, lidocaine and other sympatholytics. 
The inclusion of a rapid onset, short duration, water soluble, cardio 
selective β blocker, Esmolol to the armamentarium of the 
anaesthesiologist to control periods of intense sympathetic stimulation, 
namely laryngoscopy and endotracheal intubation adds on to the safety 
of anaesthesia. 
Dexmedetomidine is an imidazole derivative, highly selective alpha 
2 receptor agonist. It decreases central noradrenergic activity of locus 
ceruleus. It decreases systemic adrenaline and noradrenaline production. It 
has negative chronotropic and ionotropic effect and can decrease 
anesthetic doses. It may be alternative antiadrenergic therapy for 
cardiovscular response to laryngoscopy and tracheal intubation. 
In our study, we have compared the efficacy IV 
Dexmedetomidine and IV Esmolol to attenuate cardiovascular response 
during laryngoscopy and endotracheal intubation  in controlled 
hypertensive patients. 
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2. AIM OF THE STUDY 
This study was done to compare the efficacy of IV 
Dexmedetomidine and IV Esmolol in attenuating the cardiovascular stress 
responses accompanying laryngoscopy and endotracheal intubation in 
controlled hypertensive patients by measuring heart rate, systolic blood 
pressure, diastolic blood pressure and mean arterial pressure. 
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3. NERVE SUPPLY OF LARYNX 
Figure 1: Nerve Supply of Larynx 
 
The larynx is supplied by the branches of vagus viz Superior and 
Recurrent laryngeal. Superior laryngeal nerve divides into a small 
external branch and a large internal branch, where it is deep to both 
internal and external carotid arteries.  
External branch supplies cricothyroid muscle 
Internal branch after  piercing  the thyrohyoid membrane, supplies 
the  interior  of  larynx  upto  the  vocal  cords. 
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Recurrent laryngeal nerve: 
As the vagus on the right side crosses the subclavian artery, it gives 
right recurrent laryngeal nerve. It ascends to the larynx after making a loop 
under the artery and lies in the groove between oesophagus and trachea.  
As the vagus on the left side crosses the aortic arch, it gives left 
recurrent laryngeal nerve. It ascends to the larynx after making a loop 
under the aortic arch and lies in the groove between oesophagus and 
trachea.  
Once it reaches the neck both side have same relationship. Intrinsic 
muscles of the larynx except the cricothyroid is supplied by the  recurrent  
laryngeal  nerve.  It also has a sensory branch which supplies laryngeal 
mucosa below  the vocal cords.  
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4. NERVE SUPPLY OF TRACHEA 
Motor supply: 
All muscles of trachea including trachealis supplied by recurrent 
laryngeal nerve. 
Sensory supply: 
 By Recurrent laryngeal nerve 
Sympathetic supply: 
 From middle cervical ganglion 
 Connections with recurrent laryngeal nerve 
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5. PHYSIOLOGIC AND PATHOPHYSIOLOGIC 
RESPONSES TO DIRECT LARYNGOSCOPY AND 
ENDOTRACHEAL INTUBATION 
Intubation of trachea alters respiratory and cardiovascular 
physiology both via, reflex responses and by the physical presence of 
endotracheal tube. Although the reflex responses are generally of shorter 
duration and of little consequences in the majority of patients, they may 
produce profound disturbance in patients with underlying abnormalities 
such as hypertension, coronary artery disease, reactive airways and 
intracranial  pathology. 
Cardiovascular Responses: 
The cardiovascular responses to laryngoscopy and intubation are  
1. Bradycardia 
2. Tachycardia 
3. Hypertension 
Autonomic nervous system are responsible for these effects. During 
laryngoscopy and intubation, Bradycardia is often seen in infants and 
small children and very rarely in adults.  An increase in vagal tone at the 
SA node is responsible for the bradycardia. It is virtually a monosynaptic 
response to a noxious stimulus in the airway. 
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The more common response to endotracheal intubation is 
hypertension and tachycardia. Sympathetic efferents mediates this 
response via the Cardioaccelerator nerves and sympathetic chain ganglia. 
The polysynaptic pathways from the vagal and glossopharyngeal afferents 
to the sympathetic nervous system via the brain stem and spinal cord 
results in a diffuse autonomic response. This includes widespread release 
of nor-epinephrine from adrenergic nerve terminals and secretion of 
epinephrine from the adrenal medulla. Activation of the renin angiotensin 
system also produces hypertensive response to tracheal intubation, with 
the release of renin from the renal juxtaglomerular apparatus, which is an 
end organ innervated by beta adrenergic nerve terminals. 
Central Nervous System: 
In addition to activation of the autonomic nervous system, 
endotracheal intubation also stimulates CNS activity. This is evidenced by 
increasing electroencephalographic activity, cerebral blood flow, and 
cerebral metabolic oxygen requirement. 
Respiratory system: 
The effect of endotracheal intubation on the pulmonary vasculature 
is probably less well studied  than the responses elicited in the systemic 
circulation. 
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6. AIRWAY-EFFECTS OF ENDOTRACHEAL  INTUBATION 
1. Upper Airway Reflex: Laryngospasm 
Afferent pathway:  
1. Glossopharyngeal nerve  
From airway superior to the anterior surface of the epiglottis  
2 .Vagus nerve 
Airway from the level of posterior epiglottis down into the 
lower airway. 
Laryngospasm is a monosynaptic reflex primarily elicited under 
light general anesthesia when vagally innervated nerve endings are 
stimulated in the upper airway and this reflex cannot be overrided by 
conscious respiratory efforts. 
2. Dead Space: 
Normal extra thoracic  anatomical  dead  space  of  75  ml  which  on 
intubation is reduced by 60 ml. 
3. Upper Airway Resistance: 
As endotracheal tube decreases airway caliber and increases 
resistance to breathing, it provides fixed upper airway resistance which 
produces mechanical burden for spontaneously breathing patient. 
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4. Lower Airway Resistance: 
Bronchospasm and increased airway resistance may occur. Large 
airway constriction distal to the tube may occur due to stimulation of 
receptors in the larynx and upper trachea which can extend to the smaller 
peripheral airways. Following airway instrumentation, parasympathetic 
activation of airway smooth muscle can cause rapid changes in airway 
caliber.   Cholinergically induced broncho constriction is a normal airway 
response to intubation in anaesthetized patients. 
5. Endotracheal tube Resistance and Exhalation : 
 Full exhalation does not occur, as endotracheal tube may 
limit expiratory flow. 
6. Functional residual capacity (FRC) : 
Presence of endotracheal tube tends to reduce the FRC. 
7. Cough : 
Whenever an endotracheal tube is in place, Efficiency of cough is 
reduced. 
8. The gases must be warmed and humidified When the upper airway 
is bypassed following intubation. 
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7. INTUBATION AND CARDIOVASCULAR 
DISEASES 
In patients with coronary insufficiency, myocardial ischemia is the 
most common cardiovascular problem following tracheal intubation.  
Because two of the major determinants of O2 consumption namely heart 
rate and blood pressure are markedly increased during intubation. 
Transmural pressure is the main determinant of the integrity of cerebral 
and aortic aneurysms.  Accordingly  sudden increase in BP may produce 
rupture of the vessels and deterioration of the patient. 
Intubation in neurological disorders can cause dangerous increase 
in intracranial pressure and transient impairment of cerebral perfusion. 
Before the advent of neuromuscular blocking drugs, intubation 
was performed under deep levels of anaesthesia. So that little 
cardiovascular responses generated. 
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8. METHODS TO ATTENUATE CIRCULATORY 
RESPONSES DURING LARYNGOSCOPY AND 
ENDOTRACHEAL INTUBATION 
The sympathoadrenal responses should be abolished as 
maintenance of delicate balance between myocardial oxygen supply and 
demand forms the keynote in the safe conduct of anaesthesia. 
Various methods tried by various workers are 
I. Deepening of General Anaesthesia : 
Inhalational anaesthetic agents – High dose of volatile agent  was 
required to block haemodynamic response to endotracheal intubation. 
This deep level of anaesthesia achieved by inhalational agents results in 
profound cardiovascular depression prior to endotracheal intubation. 
Various agents used are Halothane, Isoflurane and Sevoflurane. 
II. Lignocaine : 
a) Lignocaine gargle for Oropharyngeal anaesthesia 
b) Aerosol for intratracheal anaesthesia 
c) Topical spray for vocal cords 
d) Regional nerve blocks – superior laryngeal nerve, glossopharyngeal 
nerve 
e) Intravenous administration. 
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Topical  anaesthesia  of  upper  airway  is  less  effective  than 
lignocaine systemic administration. 
Mechanism : 
1. By increasing the depth of general anaesthesia, 
2. Potentiation of effects of nitrous oxide anaesthesia and reduction 
of MAC for halothane by 10-28%. 
3. Direct myocardial depression, 
4. Peripheral vasodilatation 
5. Anti arrhythmic properties 
6. Suppression of cough reflex 
III. Vasodilators: 
Hydralazine 
Sodium Nitroprusside 
Nitroglycerin. 
IV. Narcotics 
Fentanyl  
Alfentanil 
Sufentanil 
Morphine 
Pethidine 
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Fentanyl is most commonly used narcotic agent.  
a) Potent analgesic 
b) Has short duration of action 
c) Does not increase intracranial tension during controlled ventilation  
d) Minimal circulatory changes 
Mechanism: 
1. The nociceptive stimulation caused by the intubation suppressed by 
analgesic effect of Fentanyl 
2. Decrease in the centrally mediated sympathetic tone. 
3. Activation of vagal tone 
V. Adrenergic Blockers: 
Long acting: Metoprolol, phentolamine, Propranolol, labetalol 
Short acting: Esmolol 
Of these, Esmolol is most commonly used agent because of its ultra 
short action. 
It reduces resting heart rate, systolic blood pressure, Ejection 
fraction and cardiac index but it maintains coronary perfusion pressure. 
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VI. Calcium channel blockers: 
  Nifedipine 
  Nicardipine 
  Diltiazem 
  Verapamil 
Nicardipine has got superior action 
VII. Alpha 2 agonist: 
Clonidine & Dexmedetomidine 
Suppresses the increase in sympathetic activity evoked by the 
intubation. 
VIII. Midazolam: 
Sedation and anxiolytic 
IX. Magnesium Sulphate: 
Sedation and anxiolytic 
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9.PHYSIOLOGY OF BETA – RECEPTORS 
Autonomic nervous system regulates body’s ongoing physiological 
function automatically by a dual function. 
First by maintaining an internal environment, and secondly by 
preparing and enabling the body to undertake extra efforts in situations of 
threat to the body’s well being. 
Parasympathetic cholinergic system is a restorative system.  
Sympathetic adrenergic is primarily stimulatory preparing the body for 
fight or flight. 
In cardiovascular system sympathetic and parasympathetic 
system are in constant opposition, and the state of the system depends 
on which system predominates. 
AHLQUIST (1960) characterized sympathetic stimulation as 
being predominantly mediated through alpha or beta receptor effects.   
Lands et al (1961) observed that beta receptor activity is due to two 
forms, beta 1 and beta 2 receptor stimulation and is responsible for the 
effect of sympathetic nervous activation on the heart, smooth muscle 
relaxation in vascular and respiratory systems, renin release, tissue 
lipolysis and glycogenolysis.  
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 Beta 1 receptor is primarily involved in cardiac effects.   In 
special circumstances like chronic cardiac failure beta 2 receptors may 
also mediate cardiac activity. 
In congestive cardiac failure beta 1 density decreases without 
changes in beta 2 receptor accounting for higher inotropic response by 
isoproterenol. 
Beta agonist posses higher affinity for coupled activator forms of 
the receptor, whereas beta antagonists have affinity for both active and 
inactive forms with no cellular activity. In addition antagonists maintain 
the receptors in a relatively inactive form so that considerably more 
agonists are required to unbalance the equilibrium. 
 
 
 
 
 
 
 
 
 19 
 
Table 1: Characteristics of Beta Adrenergic Receptors 
Receptor Agonists Tissue Responses 
Molecular 
mechanism 
Beta 1 Iso > Epi = NE 
Dobutamine 
a. Heart 
b. Juxta 
glomerular 
cells 
Force and rate of 
contraction and AV 
nodal conduction 
velocity. 
Renin secretion 
Activation of 
adenylcyclase 
and Calcium 
channels 
 
Beta 2 Iso > Epi = NE 
Terbutaline 
a. smooth 
muscles 
(vascular, 
bronchial, GIT 
and 
genitourinary)  
b. Skeletal 
muscle 
c. Liver 
Relaxation 
 
 
 
 
Glycogenolysis 
Uptake of potassium 
Glycogenolysis 
gluconeogenesis 
 
 
 
 
 
 
Activation of 
adenyl 
cyclase 
Beta 3 Iso=NE>EPi Adipose tissue Lipolysis Activation   of 
adenyl cyclase 
 
Iso   -  Isoproterenol       Epi  - Epinephrine       NE  -  Norepinephrine 
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Table 2: Site of β 1 Receptors and responses of Effector organs to 
autonomic nerve impulse. 
 
 
 
Effector organs Receptor
Type 
Adrenergic responses Cholinergic responses 
A. HEART 
 
SA Node, Atria 
 
AV Node 
 
 His-Purkinje system 
 
 Ventricle 
 
 
 
 
 
 
 
 
 
 
 
 
β1 
 
β1 
 
β1 
 
β1 
 
 
 
 
 
  ↑ H.R.  ++ 
  ↑ Contractility and     
Conduction velocity ++ 
 ↑ Automaticity  and 
conduction velocity ++ 
 
↑ Automaticity and 
conduction velocity ++ 
↑ Contractility, conduction 
velocity, automaticity and 
rate of idioventricular pace 
makers +++ 
 
 ↓ H.R. Vagal arrest +++ 
 
 
↓Contractility and 
shortened AP duration ++      
↓ Conduction velocity AV 
block +++ 
 
 
Little effect 
B. RENAL 
Arterioles 
β1  + β2  ↑Constriction /dilatation ++  
C. INTESTINE 
Motility and tone 
β1  + β2 Decrease Increase 
D. KIDNEY 
Renin secretion 
α 1 + β1 Decrease + 
 
 
 Increase ++ 
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10. BETA RECEPTOR ANTAGONISTS 
Most of the currently available β–blocking drugs are 
propranolamines.  The commercial formulation is a racemic mixture, in 
which the “L” form is the active ingredient. 
INDICATIONS 
a) Cardiac   arrhythmias   which   are   principally   due   to   
sympathetic stimulation as in phaeochromocytoma, myocardial 
infarction and arrhythmias associated with anaesthesia. 
b) Ischemic heart disease – improves Oxygen supply – demand ratio. 
c) Hypertensive cardiovascular disease – associated with a high 
plasma renin activity. 
d) Thyrotoxicosis 
e) Obstructive cardiomyopathy 
f) Phaeochromocytoma,    Hereditory    Tremors,    Anxiety    
neurosis, Schizophrenia, Drug addiction and Migraine 
Adverse Reactions: 
a. Bronchoconstriction. 
b. Cardiac Failure 
c. Peripheral vascular insufficiency  
d. Hypoglycemia 
e. Drug interaction. e.g., antidiabetics. 
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Table 3: BETA ADRENERGIC BLOCKING DRUGS 
 
 
 
 
 
Drugs 
Potency 
proprano
lol=1 
Beta 
selective 
Intrinsic 
sympatho
mimetic 
Membrane 
Stabilizing 
activity 
Lipid 
solubility 
Hepatic 
meta 
bolism 
Propranolol 1 - - + High 99 
Timolol 6 - - - Moderate 80 
Nadolol 0.8 - - - Low 27 
Metoprolol 1 + + - - Moderate 97 
Atenolol 1 + + - - Low < 10 
Pindolol 6 - + ++ + Mod/Low 60 
Oxeprenolol 1 - + + + Moderate 97 
Acebutolol 0.3 + + + High 80 
Labetalol 0.3 - - - Mod/High 90+ 
Esmolol 0.5 + + + - - Low 0-10 
 23 
 
11.PHARMACOLOGY OF ESMOLOL 
The concept of an ultrashort acting β-adrenergic blocker was 
described by ZAROSLINSKI in 1982. From this work, esmolol which is a 
cardioselective β- blocker and has an extremely short duration of action 
was subsequently identified and characterized. 
Chemistry : 
 
Esmolol is chemically Methyl p- [2-hydroxy -3 (isopropylamino) 
propoxy] hydrocinnamate hydrochloride, a molecular structure 
characteristic of second generation β -blockers.  The presence and 
location of an ester in the para position of phenyl ring is of fundamental 
importance in the determination of Esmolol’s cardioselectivity and  its 
ultrashort action. 
Esmolol has the empirical formula C16   H26   NO4   C1   and a 
molecular weight of 331.8.  It exists as an enantiomeric pair and has one 
asymmetric centre.  
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Esmolol hydrochloride is a white to off-white crystalline powder.  
It is a relatively hydrophilic compound. It is freely soluble in alcohol and 
very soluble in water. 
Clinical Pharmacology: 
Esmolol hydrochloride is a β 1–selective aderenergic receptor 
(cardioselective)  blocking agent with rapid onset, a very short duration of 
action and no significant membrane stabilizing activity or intrinsic 
sympathomimetic at therapeutic dose. Esmolol inhibits the β1 receptors 
located mainly in cardiac muscle, but their preferential effect is not 
absolute. It inhibits β2- receptors located in the bronchial and vascular 
musculature at higher doses.  Esmolol is 43 fold more potent at β receptors 
in atria (β 1) than in Trachea (β2).  Blockade of vascular β–receptors 
required a dose several – fold greater than that required for cardiac β–
blockade. Esmolol does not have any effect on peripheral vascular 
resistance. 
Pharmacokinetics and Metabolism : 
Rapid metabolism of Esmolol is due to hydrolysis of ester linkage, 
mainly by esterase in the cytosol of RBCs and not by plasma  
cholinesterase or RBC membrane acetylcholinesterase. Total body 
clearance of 20L/kg/hr is greater than cardiac output. Thus the metabolism  
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is not affected by the rate of blood flow to the metabolizing tissues such as 
the kidney and liver. It has a 2 minutes rapid distribution half-life and an9 
minutes elimination half-life. 
Steady state Esmolol blood levels are obtained within 5 minutes 
after an appropriate loading dose and within 30 minutes without loading 
dose. Blood levels of Esmolol is maintained in steady state during 
infusion, but after termination of the infusion, it rapidly falls (20 minutes).  
Since it has a short half-life, blood levels can be altered by changing the 
infusion rate.  
Metabolism of Esmolol results in the formation of an acid 
metabolite (ASL-8123) phenyl propionic acid and methanol. The acid 
metabolite has 1/1500th the activity of Esmolol and its blood levels do not 
correspond to the level of β – blockade. Acid metabolite has an 
elimination half life of about 3.7 hrs and is excreted in the urine with a 
clearance approximately equal to the glomerular filtration rate. 
Elimination of acid metabolite is significantly decreased in patients with 
renal disease with the elimination half-life increased to ten-fold that of 
normal. Esmolol is unaffected by plasma cholinesterase. For full 
enzymatic activity, the Esmolol esterase in RBC cytosol requires a heat– 
labile high molecular weight plasma component. The enzyme is not 
inhibited to any significant degree of cholinesterase inhibitor such as 
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physostigmine or echothiophate, but is totally inhibited by sodium 
fluoride. No metabolic interactions have been observed between Esmolol 
and other ester containing molecules of clinical relevance. It does not 
modify the magnitude or duration of neuromuscular blockade in response 
to succinylcholine (Richard J.Gorzynski). Esmolol is 55% bound to human 
plasma protein while acid metabolite is only 10% bound. 
In human electrophysiological studies, Esmolol effects that are 
typical of  a  β –  blocker  ; increase  in  sinus  cycle  length, decrease  in  
heart  rate, and  prolongation of sinus node recovery time. 
1. Esmolol produces reduction in heart rate, systolic blood pressure, rate 
pressure product and right ventricular ejection fraction and cardiac index 
at rest and during exercise, similar in magnitude to propranolol, but 
produces significantly  lower  fall  in  systolic  blood  pressure  ;  
Esmolol  also  produces small, clinically insignificant increase in left 
ventricular end-diastolic pressure and pulmonary capillary wedge 
pressure.  30 minutes after discontinuation of infusion all the 
haemodynamic parameters return to pretreatment levels. 
2. In asthmatic patients, Esmolol infusion is cardioselective of without 
significant increase in specific airway resistance   Unlike Esmolol, 
propranolol produces significant bronchospasm requiring bronchodilator  
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therapy. In COPD patients,  Esmolol shows no adverse pulmonary 
effects. 
3. Esmolol is very effective in the management of atrial fibrillation, atrial 
flutter and supraventricular tachycardia.  
There is significant decrease in blood pressure compared to 
propranolol but was rapidly reversible with decreased infusion rates or on 
discontinuation. Hypotension was less frequent in those patients receiving 
concomitant digoxin. 
Drug Interactions: 
Catecholamine depleting drugs (eg. Reserpine) may have an 
additive effect when given with Esmolol.  So patients should be observed 
for hypotension or marked bradycardia. 
Esmolol concentrations were higher when given with warfarin but 
this is of no clinical importance.   When given with digoxin blood levels 
of digoxin were high and when given with morphine blood levels of 
Esmolol were high. 
Indications : 
For rapid control of ventricular rate as in atrial flutter or fibrillation.  
For short term control of ventricular rate when short acting agents are 
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desirable as in (SVT, unstable angina, myocardial infarction) and to 
control perioperative tachycardia. 
Contraindications: 
In patients with sinus bradycardia, heart block, cardiogenic shock 
and overt cardiac failure, diabetics and end stage renal disease. 
Adverse Reactions : 
CVS – Symptomatic hypotension occurs in 12% of patients. 
Asymptomatic hypotension in 25% of patients.  Hypotension gets resolved 
on discontinuation of treatment. Very rarely bradycardia, chest pain, 
syncope, sinus pause and asystole occur all reversible with discontinuation 
of treatment. 
CNS : Dizziness, Headache, agitation and fatigue. 
RS : Bronchospasm, nasal congestion – relatively less. 
GIT : Nausea, vomiting, constipation, Diarrhoea, Drymouth. 
Skin : Inflammation, and induration at the site of infusion, 
Oedema, skin discolouration, thrombophlebitis and local skin necrosis. 
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Acute Toxicity: 
Accidental massive overdose when it occurs is due to an error in 
dilution. It can cause hypotension, bronchospasm, drowsiness, bradycardia 
and loss of consciousness. These are resolved within ten minutes of 
discontinuation or with administration of a pressor agent. 
Compatibility : 
Compatible with commonly used intravenous fluids except sodium 
bicarbonate injection. 
Preparations Available : 
100 mg       -        10 ml vial 
2.5 g           -        10 ml amp 
Dosage : 
To attenuate the sympathoadrenal response during laryngoscopy and 
intubation, the dosage is 1.5 mg/kg as bolus or as an infusion at the rate of 
500 mcg/kg/minute for 2 minutes as loading dose followed by a 
maintenance dose of 100 mcg/kg/minute. 
To initiate treatment of a patient with supraventricular tachycardia, a 
loading dose of 500 mcg/kg/minute for 1 minute followed by   
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maintenance infusion of 50 mcg/kg/minute for 4 minutes.  If an adequate 
therapeutic effect is not observed within 5 minutes, the same loading dose 
can be repeated and followed with a maintenance infusion increased to 100 
mcg/kg/min, therapeutic plasma level being 400-1200 nano gm/ml.  The 
time to 100% recovery is 30 minutes. 
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12.PHARMACOLOGY OF DEXMEDETOMIDINE 
 
Dexmedetomidine is an a2- agonist that received FDA approval 
in 1999. It is indicated for short-term(less than 24 hrs) sedative 
analgesic especially in the ICU(3).  Clonidine is the prototype of alpha 
2 agonists. It is widely used as an anaesthetic adjuvant and in pain 
medicine but little as a sedative. Dexmedetomidine is a highly 
selective α 2- adrenoceptor agonist than clonidine and hence it can be 
used in high doses for sedation and analgesia without the unwanted 
side effects from the activation of α 1- receptors(4). Dexmedetomidine is 
a shorter acting drug than clonidine. The sedative effect of 
dexmedetomidine can be reversed by Atipamezole. It is used in 
perioperative period as a sedative, premedication agent, as an adjuvant 
for general and regional anaesthesia and also for postoperative 
sedation and analgesia. 
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PHYSIOLOGY OF α 2 ADRENORECEPTORS 
α 2 - adrenoceptors were found in central and peripheral nervous 
systems, also in effector organs like kidney, liver, pancreas, vascular 
smooth muscles, eye and platelets. 
They are divided into 3 subtypes. 
α2A – predominant subtypes in CNS, this is responsible for the 
sedative, analgesic and sympatholytic effect. Dexmedetomidine is 8 to 
10 times more selective  a2 AR agonist than Clonidine. 
α 2B – found in the peripheral vasculature, and is responsible for 
the short term hypertensive response. 
α 2C – found in the CNS, Which is responsible for the anxiolytic 
effect. 
All these subtype act at the cell level by signalling through a G-
Protein which couples to effector mechanisms, and the coupling differs 
depending on receptor sub-type and location. The a2 A-Subtype 
appears to couple in an inhibitory manner to the calcium ion channel in 
the locus ceruleus of the brain stem. 
In the vasculature, the α 2 B subtype couple in an excitatory 
fashion to the same effector mechanism. 
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MECHANISM OF ACTION OF DEXMEDETOMIDINE 
Dexmedetomidine possess unique properties and it differs from 
other sedative drugs.  α 2  - adrenoceptors are found in many sites 
throughout the CNS, but the highest densities are found in the locus 
ceruleus, the important noradrenergic nuclei of the brainstem which is 
an important modulator of vigilance(5).  Presynaptic activation of α 2  A 
adrenoceptor in the locus ceruleus inhibits nor epinephrine (NE) 
release and results in sedative and hypnotic effects. 
The important modulator for nocioceptive neurotransmission is 
the descending medullospinal noradrenergic pathway and it originates 
from locus ceruleus of brainstem. Stimulation of the α 2  -adrenoceptors 
in this area terminates mainly the propagation of pain signals leading 
to analgesia. In the CNS, post synaptic activation of α 2 –adrenoceptors 
may produce hypotension and bradycardia because of decrease in 
sympathetic activity. Also cardiac vagal activity is augmented and all 
the effects together produce sedation, analgesia,  and anxiolysis. 
Activation of α 2  -receptors at the substantia gelatinosa of dorsal 
horn at the spinal cord causes inhibition of the nociceptive neurons 
firing and also inhibition of substance P release. The peripheral α 2  
adrenoceptors also have anti nocioception action by preventing NE 
release at the nerve endings resulting in analgesia. The spinal action is 
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the principal mechanism for the analgesia, but evidence exists for both 
supraspinal and peripheral sites of action. 
α2 – receptors located on blood vessels mediates vasoconstriction 
whereas those located on sympathetic terminals inhibit NE release. In 
other areas these adrenoceptors cause contraction of vascular and other 
smooth muscles, decrease in salivation, decrease in secretion and 
motility of bowel in the gastrointestinal tract. It also causes inhibition 
of renin release leading to increase in glomerular filtration, increase in 
secretion of sodium and water by the kidney.  α 2 - adrenoceptors 
activation also causes decrease in insulin release from pancreas, 
decrease in intraocular pressure, decrease in platelet aggregation and 
decrease in the shivering threshold by 2°C.(6)     
PHARMACOKINETICS, ABSORPTION AND 
DISTRIBUTION 
Dexmedetomidine, is the active d-isomer of medetomidine. It is 
an imidazole derivative. Dexmedetomidine in doses between 0.2 to 0.7 
mcg/kg /hr exhibits linear pharmacokinetics and it is administered as 
intravenous infusion upto 24 hours. It has 6 minutes half life of 
distribution and 2 hours half life for elimination, Because it has the 
rapid distribution phase. 
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The steady-state volume of distribution is 118L. Average protein 
binding is 94%. Context- sensitive half life ranges from 4 minutes to 
250 minutes for infusion duration of 10-minutes to 8-hours. Because 
of its extensive first-pass metabolism, its oral bioavailability is poor. 
The bioavailability of sublingual route is high (84%) and it 
offers a potential role in paediatric sedation and premedication (7) . 
The pka of dexmedetomidine is 7.1 and is freely soluble in 
water. For sedation, it has to be given as a loading dose of 1µg/kg i.v 
over 10 minutes and maintenance dose by an infusion of 0.2 - 
0.7µg/kg/hr. 
METABOLISM AND EXCRETION 
Dexmedetomidine undergoes biotransformation into its inactive 
metabolites through direct N- glucuronidation and cytochrome P-450 
(CYP 2A6) mediated aliphatic hydroxylation. Metabolites are excreted 
in urine (95%) and in the faeces (4%). Dose has to be reduced in 
patients with hepatic failure and renal failure. 
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PHARMACODYNAMICS OF DEXMEDETOMIDINE 
α 2 - adrenoceptor agonists have different a2 / a1 selectivity.  a2/ a1 
selectivity of dexmedetomidine is 1620:1 whereas it is low for 
clonidine (220:1) and hence dexmedetomidine is 8 times more specific 
a2 - adrenoceptor agonist than clonidine. 
CARDIOVASCULAR SYSTEM 
Dexmedetomidine does not have any direct action on the heart. 
It causes a dose dependent increase in the coronary vascular resistance 
and oxygen extraction, leading to alteration in the supply / demand 
ratio. It exhibits a biphasic response in blood pressure with short 
hypertensive phase followed by subsequent hypotension. 
RESPIRATORY SYSTEM 
Dexmedetomidine does not produce respiratory depression even 
at high doses(8) . It can be used in spontaneously breathing ICU 
patients and after surgery. It maintains sedation without cardiovascular 
instability or respiratory drive depression. Hence it is used during 
weaning and extubation in surgical ICU /trauma   patients in whom 
previous weaning attempts have failed because of agitation associated 
with hyperdynamic cardio pulmonary response (9) . 
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CENTRAL NERVOUS SYSTEM 
Cerebral blood flow and cerebral metabolic requirement of 
oxygen are reduced by Dexmedetomidine. Dexmedetomidine enhances 
cumulative performance and also possess sedative, analgesic and 
anxiolytic action through α 2 –AR(10) . Brain and circulating 
catecholamines levels are reduced, thus balancing the ratio between 
cerebral oxygen supplies and reduces excitotoxicity. Hence it 
improves the perfusion in the ischemic penumbra, and possess 
excellent neuroprotective action. In subarachnoid haemorrhage it 
reduces the levels of glutamate which is responsible for cellular brain 
injury. 
ENDOCRINE AND RENAL EFFECTS 
Dexmedetomidine activates peripheral presynaptic α2 -AR, thus 
catacholamine release is reduced and hence sympathetic response to 
surgery is also reduced. It is an imidazole agent but does not inhibit 
steroidogenesis when used as an infusion for short term sedation(11) . 
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ADVERSE EFFECTS 
1. Hypotension & hypertension 
2. Bradycardia & atrial fibrillation 
3.  Dry mouth 
4. Nausea & vomiting 
5.  Pulmonary edema 
6. Pleural effusion & atelectasis 
7.  Pyrexia & chills 
8. Hyperglycemia & hypocalcaemia 
9. Acidosis, etc.,  
Transient hypertension is produced when dexmedetomidine 
infusion is rapidly administered (Loading dose of 1µg/Kg / hr given in 
less than 10 minutes) and this is mediated by vasoconstriction on 
action at peripheral α 2B-AR(12) . 
The occurrence of hypotension and bradycardia is mediated by 
central α2A-AR(13) , causing decrease of noradrenaline release from the 
sympathetic nervous system. Supersensitization and up regulation of 
receptors occur during long term use, hence abrupt discontinuation not 
advised. Withdrawal syndrome, nervousness, headache, hypertensive 
crisis, and agitation occur during abrupt discontinuation. 
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USES OF DEXMEDETOMIDINE 
 PREMEDICATION 
Dexmedetomidine is used as an adjuvant for premedication since 
this drug possess sedative, analgesic, anxiolytic, sympatholytic, and 
stable hemodynamic profile. It potentiates the anaesthetic effects of all 
intraoperatively used anesthetics (intravenous, volatile or regional 
block). In a study by Bohrei et al, preoperative administration of 
dexmedetomidine either intravenous or intramuscular resulted in a 
decrease in the induction dose of thiopentone by upto 30%(14) . 
Dexmedetomidine can also be used as a premedication in 
paediatric anaesthesia either orally or nasally(15) .  Dexmedetomidine 
in a dose of 1 µg/kg intramuscularly used as a premedication in 
outpatient ophthalmic surgery resulted in sedation, and decrease in 
intraocular pressure without significant bradycardia or hypotension(16). 
Dexmedetomidine as a premedication reduces oxygen consumption 
intraoperatively by 8% and in post operative period by 17% (17) . 
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AS AN ADJUVANT TO GENERAL ANASTHESIA 
Intraoperatively dexmedetomidine produces hemodynamic 
stability by attenuating the haemodynamic response to intubation, 
during surgery, during extubation and emergence from anaesthesia (18) . 
It reduces the maintenance concentration of various inhalational 
anaesthetic agents and also produces intraoperative and postoperative 
opioid sparing effect. It reduces the shivering threshold and can be 
used to prevent and treat shivering. 
USE OF DEXMEDETOMIDINE IN REGIONAL 
ANAESTHESIA 
Dexmedetomidine seems to be promising adjuvant in the field of 
regional anaesthesia. It is used as an effective adjuvant in central 
neuraxial blocks, minor and major peripheral nerve blocks. Highly 
lipophilic nature of dexmedetomidine facilitates rapid absorption into 
the cerebrospinal fluid. It binds to a2 - AR of spinal cord for its 
analgesic action(19) . Sensory and motor block produced by local 
anaesthetics is prolonged. It is also used in brachial plexus block, 
intravenous regional anaesthesia (IVRA), and intraarticularly. It is also 
given through intraarticular route in arthroscopic knee surgeries to 
improve the duration of postoperative analgesia (20) . 
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SEDATION IN ICU 
Dexmedetomidine produce cooperative sedation. It does not 
interfere with the respiratory drive hence it facilitates early weaning 
from ventilator, thus reducing ICU stay costs(21) . Many studies have 
recommended their use for longer than 24 hrs. Other beneficial effects 
are analgesic sparing effects, minimal respiratory depression, reduced 
delirium and agitation,  and desirable cardio vascular effects. 
MONITORED ANAESTHESIA CARE 
Dexmedetomidine is used for short term procedural sedation like 
transesophageal echocardiography(22) , shockwave lithotripsy(23) , 
colonoscopy(24) ,  awake carotid endarterectomy(25) , paediatric MRI(26)  
, and elective awake fiberoptic intubation (27) . The dose is 1 µg/kg 
which is followed by an infusion of 0.2µg/kg/h. 
CONTROLLED HYPOTENSION 
Spinal fusion surgery for idiopathic scoliosis (28) , tympanoplasty 
and septoplasty operations(29)  and maxillofacial surgery(30)  have been 
done with dexmedetomidine induced hypotension. 
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ANALGESIA 
Dexmedetomidine activates a2 -AR in the spinal cord, resulting 
in a reduced transmission of nocioceptive signals. It possesses 
significant opioid sparing effect. 
CARDIAC SURGERY 
Dexmedetomidine reduces the extent of myocardial ischemia 
during cardiac surgery(31) .  Its other uses are in the management of 
pulmonary hypertension in patients undergoing mitral valve 
replacement(12) . 
NEUROSURGERY 
Dexmedetomidine possess neuroprotective effect. It also 
attenuates delirium and agitation, so that postoperative neurological 
evaluation will be easier. It has a role in functional neurosurgery like 
awake craniotomy surgeries and implantation of deep brain stimulators 
for Parkinson’s disease(32) . 
OBESITY 
In morbidly obese patients this drug does not cause respiratory 
depression in the dose of 0.7µg /kg intra operatively. 
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OBSTETRICS 
Intravenous dexmedetomidine is used as an adjuvant along with 
systemic opioids for labour analgesia(33) . Because of its high 
lipophilicity, it is retained in the placenta and less readily enters the 
fetal circulation than clonidine. Thus the chance of fetal bradycardia is 
less. 
PAEDIATRICS 
Recently it is used in paediatric patients for sedation during non-
invasive procedures in radiology like CT scan and MRI(34) .    It is also used 
for sedation in PICU settings, various invasive surgical procedures like 
upper GI scopy, colonoscopy, fiberoptic intubation(35) . Dexmedetomidine 
is also used in paediatric open heart surgeries to attenuate the 
hemodynamic and neuroendocrine stress response to surgical trauma and 
cardiopulmonary bypass(36) . 
OTHER USES 
Used as an anti-shivering agent. Also used in the treatment of 
withdrawal from opioids, benzodiazepines, and alcohol. 
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13.REVIEW OF LITERATURE 
Though laryngoscopy and intubation were performed with ease in 
earlier  years, the Anaesthesiologists had to struggle to combat or subdue 
the circulatory or cardio vascular effects of the said procedure in patients 
with compromised circulatory system. 
RIED&BRACE(37)   (1940)   postulated   that   reflex   circulatory   
responses   to laryngeal instrumentation were mediated through the vagus 
nerve and they named it as “Vaso Vagal Reflex”. 
KING  et  al(38)  (1951)  used  deep  Ether  anaesthesia  to  abolish  
the  reflex circulatory response to tracheal intubation. 
KING and his associates(38) (1960) believed the reflex mechanisms 
to be essentially non-specific in character. They stated that the 
impulses  initiating the reflex arc are probably carried over the vagus, 
while the effector system is less clearly  defined  and  may  be  due  to  
decreased  parasympathetic  or  increased sympathetic adrenal activity. 
WYCOFF C.C.(39) (1960) in his study stated that topical anaesthesia 
of the pharynx along with Superior laryngeal nerve blocks reduced the 
increase in mean arterial pressure after intubation. 
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FORBES and DALLY(40) (1970) observed that laryngoscopy and 
endotracheal intubation is immediately associated with an average increase 
in mean arterial pressure of 25mm of Hg in all 22 normotensive patients. 
These responses were interpreted as due to reflex sympathetic adrenal 
stimulation. 
PRY ROBERT et al(41) (1971) found that the increases in heart rate 
and blood pressure are much more exaggerated in hypertensive patients 
They observed 
i. Inotropic failure 
ii. Ischemic arrhythmias 
iii. CerebrovascularAccidents 
In  patients  with  uncontrolled  hypertension  who  came  up  for  
emergency surgery and associated substantial increase in heart rate and 
blood pressure following laryngoscopy and endotracheal intubation which 
lasted for several minutes. 
DENLINGER J.K and ELLISON N.E.(42) (1974) have used 
intratracheal lignocaine spray which causes a 50% reduction in the 
hypertensive response. 
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VICTORIA FARIA BALNC and NORMAND A.G.(43) (1974) in 
their article of “Complications of Tracheal Intubation” has classified the 
neurogenic or reflex mediated complication into three different categories. 
i. Laryngo Vagal Reflexes- Which give rise to spasm of the glottis, 
apnoea, bronchospasm, cardiac dysrhythmias, bradycardia,  and 
arterial hypotension. The mere presence of the tracheal tube 
seems to be the most common cause of bronchospasm in 
anaesthetized asthmatic patients. 
ii. Laryngo Sympathetic Reflexes which include 
tachyarrhythmias, tachycardia a n d  acute arterial hypertension 
as frequent   complication. During laryngoscopy, the 
hypertensive hyperdynamic state may be related to an increased 
noradrenaline fraction of the total catecholamines. 
iii. Laryngo Spinal Reflexes- which include vomiting, coughing, 
and bucking 
J.CURRAN, M.CROWLEY(44) (1980) has studied the use of 
Droperidol an alpha blocker to attenuate the pressor response. Droperidol 
administration was found to be associated with an undesirably low mean 
arterial pressure for a short period in a proportion of patients. 
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PARNASS SM, KERCHBERGER JP, ROTHENBERG DM,  
and IVANKOVICH AD(45) (1990) demonstrated that single bolus dose of 
esmolol blunted tachycardia and hypertensive response to laryngoscopy 
and endo tracheal intubation. 
STEVEN M. HELFMAN, EVERTARD A, MARTIN I GOLD, 
CLAIRE A. HERRINGTON and DE LESSER (1991)(46) observed that 
esmolol provides consistent and reliable protection from increase in both 
heart rate and systolic blood pressure during and after intubation. Where 
as lignocaine and fentanyl failed to protect against increases in heart rate 
but provided protection against increase in systolic blood pressure 
equivalent to that provided by esmolol. 
D. R. MILLER a nd  R.J . MARTENEAN(47) (1991) concluded 
that  esmolol 1.5mg/kg  is  safe  and  effective  in  controlling  
cardiovascular  responses  during anaesthetic induction. 
HELFMAN SM, GOLD MI, DELISSER EA, HERRINGTON 
CA(48) ( 1991) demonstrated that only esmolol provided consistent and 
reliable protection against increase in both heart rate and systolic blood 
pressure accompanying laryngoscopy and intubation. 
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FENQ CK, CHAN KH, LOKN, ORCH, LECTY(49)( 1996), 
observed that only esmolol could reliably offer protection against increase 
in both heart rate and systolic blood pressure, low dose fentanyl (3mcg/kg) 
prevented hypertension but not tachycardia and 2mg/kg lidocaine has no 
effect to blunt adverse haemodynamic response during layngoscopy and 
tracheal intubation. 
Suman Sharma et al(50) (1996) reported that in treated hypertensive 
patients, 100mg of Esmolol is safe and convenient method for attenuating 
haemodynamic response during layngoscopy and tracheal intubation. 
Oxorn et al.(51) (1990) reported that 100mg and 200mg of esmolol in 
bolus doses affects solely increase in heart rate in a significant manner. 
Kindler et al.(52) (1996) concluded that administration of esmolol 
was effective on attenuating increase in heart rate to tracheal intubation, 
But   not effective on attenuating the blood pressure response.  
Scheinin et al.(53) (1992) concluded that in healthy individuals 
dexmedetomidine 0.6 μg/kg decreased, but not totally abolished, the 
cardiovascular response to tracheal intubation.  
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Menda et al.(54) (2010) reported that in patients undergoing 
myocardial revascularization, dexmedetomidine when combined with 
fentanyl effectively attenuated the hemodynamic response to endotracheal 
intubation. 
Hale Yarkan Uysal et al.(55) (2012) concluded that in hypertensive 
patients, administration of dexmedetomidine in a single dose before 
induction of anesthesia was an effectively attenuate the hemodynamic 
response to tracheal intubation. 
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14. MATERIALS 
METHODOLOGY 
           A Single centre, Prospective, Randomized, Double blind study 
SAMPLE SIZE 
         Total of 60 controlled hypertensive patients (Diagnosis of SHT 
according to WHO criteria SAP≥160 mm of Hg or DAP≥90 mm of Hg)  
undergoing general anaesthesia for elective non cardiac surgery 
RANDOMIZATION AND ALLOCATION 
        60 Patients are randomly divided into 2 groups of 30 patients each by 
using sealed envelope technique 
1. Group D (Dexmedetomidine):  
consisting of 30 patients who received Dexmedetomidine 
1µg/kg in 100ml normal saline, 2 minutes prior to intubation. 
2. Group E (Esmolol): 
consisting of 30 patients who received 1.5 mg / kg Esmolol, 2 
minutes prior to intubation. 
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INCLUSION CRITERIA 
1. ASA Physical status II 
2. Well controlled Hypertensive Patients 
3. Age 30 - 60 years 
4. Both Gender 
EXCLUSION CRITERIA 
1. Patient’s refusal 
2. Secondary Hypertension 
3. Co-morbidities like DM, CAD, CVA 
4. Pregnancy 
5. Predicted Difficult Intubation 
6. Intubation time >30Secs 
7. Intubation in more than one attempt.  
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Preoperative preparations: 
Age 
I.P.No 
Body weight 
Baseline vital parameters 
History  
Previous anaesthesia and Surgery 
Any co-morbidities 
Medications 
Any allergy 
Complete physical examination  
Airway assessment 
Laboratory investigations  
Hb % 
Blood Sugar  
Serum urea & Creatinine, electrolytes 
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Bleeding and clotting time 
Urine analysis 
X ray chest 
ECG 
Other investigations were obtained on the basis of the condition 
of the patient. 
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15.METHODS 
After getting institutional ethical committee approval, the procedure 
was explained to the patients and written informed consent was obtained. 
All patients were premedicated with injection Midazolam 0.05 
mg/kg and Injection glycopyrrolate 0.2 mg intramuscularly 45 minutes 
before surgery.   
In operating room, IV line was established. Patients were monitored 
by NIBP,ECG, SpO2 and 0.9% NaCl was started at the rate of volume 
based on fluid deficit and maintainence fluid according to patients body 
weight. Baseline Parameters (HR, SAP, DAP, MAP and SpO2) were 
recorded. 
Group D received 1µg/kg of Dexmedetomidine in 100 ml 0.9% 
NaCl over 10 minutes. Group E received 1.5mg/kg of Esmolol over 1 min. 
An anaesthesiologist who is not involved in the study, administered the 
study drug. 
After 2 min, Patient induced with thiopentone sodium 5 mg/kg, 
fentanyl 2 µg/kg and atracurium 0.5mg/kg. All patients were ventilated via 
face mask. Laryngoscopy and endotracheal intubation is done by 
appropriate size cuffed endotracheal tube. Anaesthesia was maintained 
with controlled ventilation with nitrous oxide 66% and oxygen 33%. 
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HR,SAP,DAP,MAP and SpO2 were recorded Baseline(T1), after 
drug administration(T2), after induction(T3), 0, 1, 3, 5, 10, 15 min after 
intubation(T4-T9). No surgical intervention was allowed throughout the 
study period. 
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16.STATISTICAL ANALYSIS 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done by using statistical 
package for social sciences version 16.  
All data were expressed as mean ± 2 SD. Student 't' test and 
Pearson chi square were used to analyze the nominal data. Paired 't' test 
was used to compare intra group variation.  A 'p' value less than 0.05 is 
taken to denote significant relationship. 
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17.OBSERVATION AND RESULTS 
60  patients  under  this  study  were  categorized  into  2  
groups(Group D & Group E).    They comprised both sexes with age 
ranging from 30-60 years. 
Demographic profile, type of anti hypertensive medications and 
baseline parameters between two groups were comparable and were not 
statistically significant (P>0.05). 
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AGE 
Table 4: AGE 
 MEAN ±SD P VALUE 
GROUP D 44.4 ±7.2 
0.884 
GROUP E 44.4 ±8.62 
 
Figure 2: AGE 
 
 
The mean age of the patients is 44.4 in Group D & E. There is no 
significant difference in the age composition of the cases in the two 
groups(P 0.884). 
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SEX 
Table 5: SEX 
Groups 
GENDER 
Total P value 
Male Female 
Group D 10 20 30 
0.592 Group E 12 18 30 
Total 22 38 60 
 
Figure 3: SEX 
 
There is no significant difference in the sex composition of the 
cases in the two groups (P 0.592). 
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ANTI HYPERTENSIVE MEDICATION 
Table 6: ANTI HYPERTENSIVE MEDICATION 
Groups 
ANTI HYPERTENSIVE DRUGS 
Total P value 
None ACEI Diuretics 
Beta 
blocker 
Group D 5 11 4 10 30 
0.954 Group E 6 10 3 11 30 
Total 11 21 7 21 60 
 
Figure 4: ANTI HYPERTENSIVE MEDICATION 
 
 There is no statistical difference in anti hypertensive drugs taken by 
patients in two groups (P 0.954). 
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BASELINE PARAMETERS 
Table 7: BASELINE PARAMETERS 
PARAMETERS GROUP Mean 
Std. 
Deviation 
t value P value 
HR 
D 79.97 5.70 
1.02 0.314 
E 78.47 5.74 
SAP 
D 122.20 10.55 
-0.84 0.402 
E 124.57 11.17 
DAP 
D 76.27 8.36 
-0.33 0.740 
E 76.93 7.07 
MAP 
D 90.93 8.58 
-0.79 0.434 
E 92.60 7.77 
SPO2 
D 98.70 1.26 
-0.76 0.429 
E 98.57 1.33 
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 Figure 5: BASELINE PARAMETERS 
 
 The mean HR, SAP, DAP, MAP & SPO2 of the patients were 79.97, 
122.20, 76.27, 90.93 & 98.70 in Group D and 78.47, 124.57, 76.93, 92.60 
& 98.57 in Group E respectively. There is no statistical difference in 
baseline parameters between two groups. 
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HEART RATE 
Table 8: HEART RATE 
Time GROUP Mean 
Standard 
Deviation 
t value P value 
T1 
D 79.97 5.70 
1.02 0.314 
E 78.47 5.74 
T2 
D 78.20 5.91 
-2.17 0.034 
E 81.20 4.72 
T3 
D 83.07 9.93 
-3.20 0.002 
E 90.27 7.29 
T4 
D 79.67 6.94 
-6.48 <0.0001 
E 89.03 3.81 
T5 
D 87.00 11.52 
-4.23 <0.0001 
E 98.60 9.62 
T6 
D 81.57 8.32 
-4.58 <0.0001 
E 94.07 12.43 
T7 
D 82.07 8.12 
-7.97 <0.0001 
E 98.43 7.78 
T8 
D 78.76 7.26 
-0.85 0.398 
E 80.43 7.89 
T9 
D 78.43 7.13 
0.08 0.934 
E 78.30 5.14 
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Figure 6: HEART RATE 
 
 In Dexmedetomidine group (Group D), the mean basal heart 
rate was 79.97 beats / minute and reached maximum of 87 beats / minute at 
1 min after laryngoscopy   and endotracheal intubation and came back to 
the basal value of 78.6 beats / minute at 10 minutes. 
In Esmolol group (Group E), the mean basal heart rate was 78.47 
beats / minute which reached maximum of 98.6 beats / minute following 
laryngoscopy and endotracheal intubation and came back to the basal value 
of 78.37 beats/minute at 15 minutes following laryngoscopy and 
intubation. 
There is statistical significant lower heart rate in group D compared 
to group E at T3 to T7. 
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SYSTOLIC ARTERIAL PRESSURE 
Table 9: SAP 
Time GROUP Mean 
Standard 
Deviation 
t value P value 
T1 
D 122.20 10.55 
-0.84 0.402 
E 124.57 11.17 
T2 
D 119.97 10.71 
-1.20 0.235 
E 123.13 9.72 
T3 
D 124.03 17.60 
-0.95 0.346 
E 127.40 8.03 
T4 
D 119.20 13.01 
-3.32 0.002 
E 128.80 9.00 
T5 
D 128.27 14.95 
-4.93 <0.0001 
E 147.40 15.12 
T6 
D 129.43 13.47 
-3.09 0.003 
E 141.83 17.38 
T7 
D 129.43 12.34 
-5.88 <0.0001 
E 147.33 11.20 
T8 
D 127.00 10.63 
-1.84 0.071 
E 134.03 18.03 
T9 
D 124.97 9.91 
-1.66 0.102 
E 130.47 15.17 
 
 
 
 66 
 
Figure 7: SAP 
 
 
In Dexmedetomidine group (Group D), the mean basal systolic 
blood pressure 122.2 mm of Hg and reached maximum of 129.43 mm of 
Hg at 1 minute following laryngoscopy and endotracheal intubation and 
came back to the basal value  at 10 minutes. 
In Esmolol group (Group E), the mean basal systolic blood 
pressure was 124.57 mm of Hg and reached maximum of 144.40 mm of 
Hg at 1 minute following laryngoscopy and endotracheal intubation and 
came back to the basal value  at 15 minutes following intubation. 
There is statistical significant lower SAP in group D compared to 
group E at T4 to T7. 
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DIASTOLIC ARTERIAL PRESSURE 
Table 10: DIASTOLIC ARTERIAL PRESSURE 
Time GROUP Mean 
Standard 
Deviation 
t value P value 
T1 
D 76.27 8.36 
-0.33 0.740 
E 76.93 7.07 
T2 
D 77.10 8.23 
-0.05 0.960 
E 77.20 7.25 
T3 
D 81.90 13.84 
-1.50 0.137 
E 86.50 9.36 
T4 
D 77.70 9.64 
-4.17 <0.0001 
E 86.37 6.04 
T5 
D 84.90 15.20 
-3.35 0.001 
E 96.37 10.99 
T6 
D 85.03 12.89 
-2.37 0.021 
E 92.37 11.03 
T7 
D 86.20 13.50 
-4.35 <0.0001 
E 98.53 7.65 
T8 
D 82.56 12.09 
0.13 0.890 
E 82.16 10.07 
T9 
D 80.93 10.28 
-0.77 0.445 
E 82.96 10.17 
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Figure 8: DIASTOLIC ARTERIAL PRESSURE 
 
In Dexmedetomidine group (Group D), the mean diastolic blood 
pressure was 76.27 mm Hg and reached maximum of 86.2 at 1 minute 
following laryngoscopy and endotracheal intubation and came back to 
the basal value at 10 minutes following intubation. 
In Esmolol group (Group E), the mean diastolic blood pressure 
was 76.93 mm of Hg and reached maximum of 98.53 mm of Hg at 1 
minute following laryngoscopy and endotracheal intubation and came 
back to the basal value at 15 minutes following intubation. 
There is statistical significant lower DAP in group D compared to 
group E at T4 to T7 
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MEAN ARTERIAL PRESSURE 
Table 11: MEAN ARTERIAL PRESSURE 
Time GROUP Mean 
Standard 
Deviation 
t value P value 
T1 
 
D 90.93 8.58 
-0.79 0.434 
E 92.60 7.77 
T2 
 
D 91.39 8.43 
-0.56 0.579 
E 92.51 7.06 
T3 
 
D 95.94 14.49 
-1.36 0.176 
E 100.13 8.40 
T4 
 
D 91.56 10.07 
-4.18 <0.0001 
E 100.53 6.07 
T5 
 
D 99.36 14.59 
-4.07 <0.0001 
E 113.38 11.94 
T6 
 
D 99.83 12.70 
-2.79 0.007 
E 108.86 12.35 
T7 
 
D 100.61 12.66 
-5.26 <0.0001 
E 114.80 7.60 
T8 
 
D 97.37 10.80 
0.72 0.477 
E 99.45 11.67 
T9 
D 95.67 9.21 
-1.21 0.228 
E 98.80 10.99 
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Figure 9: MEAN ARTERIAL PRESSURE 
 
In Dexmedetomidine group (Group D), the mean MAP was 90.93 
mm of Hg and reached maximum of 100.61 mm of Hg at 1 minute 
following laryngoscopy and endotracheal intubation and came back to 
the basal value at 10 minutes following intubation. 
In Esmolol group (Group E), the mean MAP was 92.6 mm of Hg 
and reached maximum of 114.8 mm of Hg at 1 minute following 
laryngoscopy and endotracheal intubation and came back to the basal 
value at 15 minutes following intubation. 
There is statistical significant lower MAP in group D compared to 
group E at T4 to T7. 
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COMPARISON OF HEART RATE IN GROUP D 
Table 12: COMPARISON OF HEART RATE IN GROUP D 
TIME 
Paired 
Differences 
Mean 
Standard 
Deviation 
t value P value 
T2 1.77 7.76 1.25 0.223 
T3 -3.10 12.79 -1.33 0.195 
T4 0.30 9.55 0.17 0.865 
T5 -7.03 14.62 -2.63 0.013 
T6 -1.60 10.30 -0.85 0.402 
T7 -2.10 10.11 -1.14 0.265 
T8 1.20 9.23 0.71 0.482 
T9 1.53 9.09 0.92 0.363 
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Figure 10: COMPARISON OF HEART RATE IN GROUP D 
 
  
 There is no statistical significant change of heart rate compared to 
baseline in Group D. 
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COMPARISON OF SYSTOLIC ARTERIAL PRESSURE IN 
GROUP D 
Table 13: COMPARISON OF SYSTOLIC ARTERIAL PRESSURE 
IN GROUP D 
TIME 
Paired 
Differences 
Mean 
Standard 
Deviation 
t value P value 
T2 2.23 5.59 2.19 0.037 
T3 -1.83 14.89 -0.67 0.506 
T4 2.93 11.29 1.42 0.165 
T5 -6.07 13.19 -2.52 0.078 
T6 -7.23 11.71 -3.38 0.062 
T7 -7.23 11.15 -3.55 0.062 
T8 -4.80 9.64 -2.73 0.081 
T9 -2.77 8.65 -1.75 0.090 
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Figure 11: COMPARISON OF SYSTOLIC ARTERIAL PRESSURE 
IN GROUP D 
 
There is no statistical significant change of SAP compared to 
baseline in Group D. 
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COMPARISON OF DIASTOLIC ARTERIAL PRESSURE 
IN GROUP D 
Table 14: COMPARISON OF DIASTOLIC ARTERIAL PRESSURE 
IN GROUP D 
TIME 
Paired 
Differences 
Mean 
Std. 
Deviation 
t value P value 
T2 -0.83 4.81 -0.95 0.350 
T3 -5.63 11.16 -2.76 0.070 
T4 -1.43 6.38 -1.23 0.229 
T5 -8.63 13.01 -3.64 0.061 
T6 -8.77 10.46 -4.59 0.058 
T7 -9.93 11.57 -4.70 0.051 
T8 -6.30 9.23 -3.73 0.067 
T9 -4.60 7.66 -3.33 0.082 
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Figure 12: COMPARISON OF DIASTOLIC ARTERIAL PRESSURE 
IN GROUP D 
 
There is no statistical significant change of DAP compared to 
baseline in Group D. 
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COMPARISON OF MEAN ARTERIAL PRESSURE IN  
GROUP D 
TABLE 15: COMPARISON OF MEAN ARTERIAL PRESSURE IN 
GROUP D 
TIME 
Paired 
Differences 
Mean 
Standard 
Deviation 
t value P value 
T2 -0.46 4.20 -0.59 0.557 
T3 -5.01 11.56 -2.37 0.025 
T4 -0.62 7.20 -0.47 0.639 
T5 -8.42 12.07 -3.82 0.052 
T6 -8.90 10.11 -4.82 0.058 
T7 -9.68 10.45 -5.07 0.057 
T8 -6.44 8.06 -4.37 0.064 
T9 -4.67 6.76 -3.78 0.054 
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Figure 13: COMPARISON OF MEAN ARTERIAL PRESSURE IN 
GROUP D 
 
There is no statistical significant change of MAP compared to 
baseline in Group D. 
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COMPARISON OF HEART RATE IN GROUP E 
Table 16: COMPARISON OF HEART RATE IN GROUP E 
TIME 
Paired 
Differences 
Mean 
Standard 
Deviation 
t value P value 
T2 -2.73 2.77 -5.41 <0.0001 
T3 -11.80 6.49 -9.96 <0.0001 
T4 -10.57 4.99 -11.59 <0.0001 
T5 -20.13 9.46 -11.66 <0.0001 
T6 -15.60 10.73 -7.96 <0.0001 
T7 -19.97 9.26 -11.81 <0.0001 
T8 -1.96 7.49 -1.43 0.162 
T9 0.16 6.61 0.14 0.891 
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Figure 14: COMPARISON OF HEART RATE IN GROUP E 
 
There is statistical significant (Higher) change of HR compared to 
baseline in Group E at T2 to T7. 
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COMPARISON OF SYSTOLIC ARTERIAL PRESURE IN 
GROUP E 
Table 17: COMPARISON OF SYSTOLIC ARTERIAL PRESSURE 
IN GROUP E 
TIME 
Paired 
Differences 
Mean 
Std. 
Deviation 
t value P value 
T2 1.43 9.53 0.82 0.417 
T3 -2.83 10.89 -1.45 0.165 
T4 -4.30 13.29 -1.77 0.087 
T5 -22.83 15.74 -7.95 <0.0001 
T6 -17.27 18.66 -5.07 <0.0001 
T7 -22.77 17.73 -7.03 <0.0001 
T8 -9.47 17.47 -2.97 0.006 
T9 -5.90 15.14 -2.13 0.041 
 
 
 
 82 
 
Figure 15: COMPARISON OF SYSTOLIC ARTERIAL PRESSURE 
IN GROUP E 
 
There is statistical significant (Higher) change of SAP compared to 
baseline in Group E at T5 to T8. 
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COMPARISON OF DIASTOLIC ARTERIAL PRESSURE 
IN GROUP E 
Table 18: COMPARISON OF DIASTOLIC ARTERIAL PRESSURE 
IN GROUP E 
TIME 
Paired 
Differences 
Mean 
Standard 
Deviation 
t value P value 
T2 -0.27 7.72 -0.19 0.851 
T3 -9.56 10.39 -5.04 <0.0001 
T4 -9.43 8.95 -5.78 <0.0001 
T5 -19.43 12.64 -8.42 <0.0001 
T6 -15.43 12.75 -6.63 <0.0001 
T7 -21.60 11.18 -10.58 <0.0001 
T8 -5.23 11.27 -2.54 0.017 
T9 -6.03 11.50 -2.87 0.008 
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Figure 16: COMPARISON OF DIASTOLIC ARTERIAL PRESSURE 
IN GROUP E 
 
There is statistical significant (Higher) change of DAP compared to 
baseline in Group E at T3 to T8. 
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COMPARISON OF MEAN ARTERIAL PRESSURE IN  
GROUP E 
Table 19: COMPARISON OF MEAN ARTERIAL PRESSURE IN 
GROUP E 
TIME 
Paired 
Differences 
Mean 
Standard 
Deviation 
t value P value 
T2 0.09 7.06 0.07 0.945 
T3 -7.53 9.79 -4.21 <0.0001 
T4 -7.93 9.42 -4.61 <0.0001 
T5 -20.78 12.92 -8.81 <0.0001 
T6 -16.26 13.48 -6.60 <0.0001 
T7 -22.20 11.92 -10.20 <0.0001 
T8 -6.85 12.26 -3.06 0.005 
T9 -6.20 11.41 -2.97 0.006 
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Figure 17: COMPARISON OF MEAN ARTERIAL PRESSURE IN 
GROUP E 
 
There is statistical significant (Higher) change of MAP compared to 
baseline in Group E at T2 to T9. 
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18.DISCUSSION 
In this study, Dexmedetomidine (1mcg/kg) infusion 2 minutes prior 
to induction of anaesthesia attenuated the rise in heart rate and blood 
pressure following laryngoscopy and tracheal intubation in hypertensive 
patients, whereas Esmolol (1.5mg/kg) bolus injection 2 minutes prior to 
induction of anaesthesia, failed to protect the cardiovascular response 
following laryngoscopy and tracheal intubation in hypertensive patients. 
Esmolol, 
o Is Cardioselective β antagonist 
o Has Rapid onset of action 
o Has Short elimination half-life 
For attenuation of the cardiovascular response to laryngoscopy 
and tracheal intubation, Esmolol seems to be an appropriate 
selection.  
Miller et al.(56) (1989) concluded that the cardiovascular response 
to tracheal intubation was effectively attenuated by administration of 100 
mg bolus of esmolol in a Canadian multicentre trial. 
Sharma et al.(50)(1996) concluded that in hypertensive patients, the 
cardiovascular response to tracheal intubation was suppressed by 100 mg 
esmolol. 
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Oxorn et al.(51) (1990) reported that esmolol 100 mg and 200 mg in 
bolus doses significantly affects heart rate response to tracheal intubation. 
Kindler et al. (52) (1996) concluded that heart rate response to 
tracheal intubation was controlled by esmolol administration before 
laryngoscopy, but it did not affect SAP. 
Hale Yarkan Uysal et al. (55) (2012) reported that in hypertensive 
patients, esmolol was not effectively attenuating the blood pressure 
response but   it attenuate the heart rate response to tracheal intubation. 
In our study, esmolol 1.5mg/kg was not effective in attenuating 
cardiovascular response to laryngscopy and tracheal intubation in 
controlled hypertensive patients. 
Alpha-2 adrenoceptor agonists – Clonidine and dexmedetomidine 
o Had significant effects on the anesthetic requirements. 
o Had significant effects on the sympathoadrenal and hemodynamic 
responses induced by tracheal intubation, anaesthesia and surgery. 
Scheinin et al.(53) (1992) concluded that in healthy individuals  
dexmedetomidine 0.6 μg/kg decreased, but not totally abolished, the 
cardiovascular response to laryngscopy and tracheal intubation. 
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Menda et al.(54) (2010) reported that dexmedetomidine when 
combined with fentanyl effectively attenuated the cardiovascular response 
to endotracheal intubation in patients undergoing myocardial 
revascularization.  
Hale Yarkan Uysal et al.(55) (2012) reported that in hypertensive 
patients, there are no significant differences in HR and blood pressure 
between baseline value and after intubation value in dexmedetomidine 
group. But the mean percentage variation analysis showed an absence of 
increase in HR, SAP and DAP in dexmedetomidine group. 
Dexmedetomidine is as an effective agent for blunting the cardiovascular 
response to tracheal intubation in hypertensive patients. 
Our study demonstrated that there is no significant difference in HR, 
SAP, DAP and MAP between baseline and after intubation in 
dexmedetomidine group and also significant difference in HR, SAP, DAP 
and MAP after intubation between dexmedetomidine group and esmolol 
group in controlled hypertensive patients. 
Bradycardia and hypotension have been reported as adverse effect of 
dexmedetomidine in previous studies on the effect of dexmedetomidine in 
perioperative hemodynamics. 
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 Hale Yarkan Uysal et al.(55) (2012) did not observe any bradycardia 
or hypotension contrast to the previously mentioned studies. We also did 
not observe any adverse effect in our study. 
No control group is the limitation of our study. However, we decided 
that withdrawing any medication would cause detrimental effect in 
hypertensive patients. 
 
 
 
 
 
 
 
 
 
 
  
 
 91 
 
19.SUMMARY 
Dexmedetomidine (1mcg/kg) infusion given 2 minutes prior to 
induction of anaesthesia provided consistent and reliable protection against 
increases in mean heart rate and mean systolic, diastolic and mean blood 
pressure during laryngoscopy and endotracheal intubation and thereafter, 
compared to Esmolol group. 
In Dexmedetomidine group, rise in HR, SAP, DAP and MAP 
following intubation returns to baseline after 10 minutes. But, in Esmolol 
group, rise in HR, SAP, DAP and MAP following intubation returns to 
baseline after 15 minutes. 
In this study, Dexmedetomidine attenuated the rise in heart rate and 
blood pressure following laryngoscopy and tracheal intubation in 
hypertensive patients, whereas, Esmolol failed to protect the cardiovascular 
response following laryngoscopy and tracheal intubation in hypertensive 
patients. 
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20.CONCLUSION 
Dexmedetomidine (1mcg/kg) infusion 2 minutes prior to induction 
of anaesthesia attenuated the rise in heart rate and blood pressure following 
laryngoscopy and tracheal intubation in hypertensive patients, whereas, 
Esmolol (1.5mg/kg) bolus injection 2 minutes prior to induction of 
anaesthesia, failed to protect the cardiovascular response following 
laryngoscopy and tracheal intubation. 
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22.CONSENT FORM 
ஆராய்ச்சி ஒப்புதல் படிவம் 
அறுவை சிகிச்வைக்காக முழுமயக்கம் ககாடுக்கும் ப ாது 
லாரிங்காஸ்பகாபி மற்றும் எண்ப ாட்றக்யல் இண்டுப ைன் கைய்யும் 
ப ாது ஏற் டும் அதிக இருதய துடிப்பு மற்றும் இரத்த அழுதத்வத 
குவறப் தற்காக  யன் டும் இரு மயக்க மருந்துகளின் விவைவுகள் 
 ற்றி ஆய்வு. 
க யர்  : 
ையது   : 
இனம்  : 
உள்ப ாயாளி எண் : 
ைார்டு  : 
ப ாய்   : 
அறுவை சிகிச்வை : 
விளக்கம்: 
அறுவை சிகிச்வைக்காக முழுமயக்கம் ககாடுக்கும் ப ாது 
லாரிங்காஸ்பகாபி மற்றும் எண்ப ாட்றக்யல் இண்டுப ைன் கைய்யும் 
ப ாது ஏற் டும் அதிக இருதய துடிப்பு மற்றும் இரத்த அழுதத்வத 
குவறப் தற்காக  ல்பைறு மருந்துகள் உ பயாக டுத்த டுகின்றன. 
அைற்றில் இரண்டு மருந்துகைாகிய க க்ஸ்கமடிட்ப ாகமடின் மற்றும் 
எஸ்கமாலால் மருந்துகவை  ரம்பு மூலம் உ லில் கைலுத்தி அறுவை 
சிகிச்வை கைய்ைதால் ஏற் டும்  யன்கள், விவைவுகள், 
 க்கவிவைவுகள் அவனத்தும் எனக்கு  ன்கு புரிகின்ற ைவகயில் எனது 
தாய் கமாழியில் கதளிைாக விைக்கி கூறப் ட் து. 
என்னுவ ய அவ யாைம் எந்த ைவகயிலும் இந்த அராய்ச்சி 
மூலம் கைளிபய கதரியாது என் வத அறிபைன். இந்த ஆராய்ச்சியில் 
இருந்து எந்த ப ரமும் விலகலாம் என் வதயும் அதனால் எந்த  ாதிப்பு 
ஏற்  ாது என் வதயும் அறிபைன். 
 ான் யாருவ ய நிர் ந்தமுமின்றி என் கைாந்த விருப் த்தின் 
ப ரில் சுய நிவனவு ன் இந்த ஆராய்ச்சியில்  ங்கு ககாள்ை 
ைம்மதிக்கிபறன். 
 
இ ம் :        
பததி :      ப ாயாளியின் வககயாப் ம் 
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23.PROFORMA 
COMPARATIVE EVALUATION OF DEXMEDETOMIDINE AND 
ESMOLOL FOR ATTENTUATION OF INTUBATION STRESS 
RESPONSE IN WELL CONTROLLED HYPERTENSIVE 
PATIENTS – A DOUBLE BLIND RANDOMIZED CONTROL 
STUDY 
Name: Age : Sex  : Date : 
 
 
Type of surgery:      Anaesthesia: 
Pre anaesthetic Assessment: 
Height:                 Weight:   PR:   BP: 
CVS:  RS:   PA:  CNS: 
Airway 
ASA  
Investigations: 
Hb %    
Urine:  Sugar   Albumin 
Blood: Sugar   Urea    Creatinine 
 106 
 
Premedication: 
Drug Dose Route Time 
 
1.  Inj. Midazolam 
 
0.05 mg / kg 
 
IM 
 
 
2.  Inj. Glycopyrrolate 
 
0.02 mg / kg 
 
IM 
 
 
Time 
Heart 
Rate 
SAP DAP MAP SPO2 
Baseline(T1)      
After drug 
administration(T2) 
     
After 
Induction(T3) 
     
After 
Intubation(T4) 
     
1Minute (T5)      
3Minute (T6)      
5Minute (T7)      
10Minute (T8)      
15Minute(T9)      
 
Intra operative complications : 
Recovery room condition : 
Post operative visit  : 
 
Sl.
No Age Sex
Group
(D/E)
BASELINE HEART RATE SYSTOLIC ARTERIAL PRESSURE
HR SBP DBP MAP SpO2
After
Drug
Admin
After
Induc
tion
After
Intub
ation
1
min
3
min
5
min
10
min
15
min
After
Drug
Admin
After
Induc
tion
After
Intub
ation
1
min
3
min
5
min
10
min
15
min
1 35 F D 88 120 74 89 100 71 74 72 77 71 77 68 66 110 108 106 112 116 118 115 116
2 37 F D 82 132 81 97 100 79 80 80 83 87 89 80 82 129 110 110 126 126 128 130 132
3 48 F D 79 113 69 83 97 77 81 79 80 85 85 70 72 117 120 118 122 120 124 126 124
4 43 F D 77 120 70 86 98 71 74 72 77 71 72 74 70 118 116 110 117 118 120 122 120
5 44 M D 80 112 70 83 98 73 75 70 76 73 73 74 72 114 112 110 114 120 122 114 116
6 49 M D 84 130 84 99 99 72 75 75 74 70 72 68 66 120 120 120 126 130 132 132 132
7 39 F D 83 142 91 107 99 80 82 82 89 80 80 80 82 139 146 140 142 140 137 140 142
8 46 F D 79 123 79 93 100 78 80 80 82 74 74 72 70 130 132 130 132 134 132 130 128
9 45 M D 78 130 80 96 99 72 77 75 78 70 70 70 71 128 132 126 136 130 132 136 136
10 48 F D 79 122 80 93 96 74 80 76 81 76 76 73 72 124 122 122 124 130 132 134 126
11 38 M D 84 110 64 79 98 89 92 90 95 87 87 83 80 100 99 98 110 110 112 112 112
12 48 F D 68 122 71 87 99 74 76 76 78 72 70 70 71 119 126 120 116 126 122 120 122
13 36 F D 86 110 59 75 100 80 84 80 88 89 82 82 80 114 117 120 130 132 132 132 130
14 38 F D 76 110 60 76 100 82 82 80 84 81 82 82 80 108 100 100 107 108 110 112 110
15 44 M D 86 120 80 93 100 76 76 74 77 78 78 75 77 110 110 108 120 126 124 122 124
16 50 F D 85 102 72 81 98 81 82 80 86 88 88 74 73 104 102 102 110 110 110 109 106
17 42 M D 86 132 78 95 98 74 79 70 78 78 78 77 75 130 130 130 135 132 132 135 131
18 32 F D 79 114 66 81 98 78 78 78 80 81 82 82 80 115 113 110 112 122 120 116 114
19 43 F D 89 140 77 98 99 84 86 86 90 90 90 89 90 122 109 110 118 120 120 120 119
20 52 F D 78 117 83 94 96 74 72 70 78 78 80 80 81 103 100 100 110 112 114 114 110
21 40 M D 84 110 76 87 100 82 84 84 88 87 89 90 90 110 110 106 120 120 122 122 118
22 32 F D 86 129 91 102 100 68 70 70 77 77 78 80 82 129 130 124 132 132 130 132 132
23 54 M D 72 116 68 84 98 83 90 88 95 90 92 80 85 116 142 130 140 145 140 120 118
24 58 F D 72 140 86 104 99 80 120 80 121 95 95 80 79 140 134 128 142 148 146 142 140
25 60 F D 80 136 88 104 97 86 92 90 102 98 98 84 82 136 162 140 150 160 156 138 122
26 55 F D 78 134 81 98 100 92 96 90 98 92 92 80 82 134 154 130 149 145 144 127 130
27 50 M D 74 110 70 83 100 79 84 80 107 76 77 76 78 110 133 128 144 141 142 138 130
28 44 M D 86 126 80 95 97 89 92 90 92 80 81 90 92 126 162 148 166 158 158 150 143
29 42 F D 71 120 78 91 98 74 98 95 111 97 98 100 91 120 128 124 138 132 132 128 128
30 40 F D 70 124 82 95 100 74 81 78 88 76 77 80 82 124 142 130 148 140 140 142 138
31 46 F E 76 110 71 83 99 78 98 87 125 120 122 80 83 110 118 122 144 150 152 152 140
32 54 M E 76 124 83 96 99 78 82 87 105 92 93 70 70 124 122 136 148 162 164 112 114
33 56 F E 78 116 73 87 100 82 74 85 108 107 92 85 76 116 125 124 124 102 130 102 104
34 60 F E 76 141 88 106 99 84 86 90 88 80 99 70 80 141 135 118 152 132 136 139 141
35 58 F E 71 126 82 96 99 75 79 90 86 80 100 82 74 126 135 120 146 138 141 122 124
36 36 M E 76 109 78 88 97 82 86 85 92 81 103 76 78 109 124 130 136 125 162 110 112
37 37 M E 81 132 80 97 96 86 86 90 84 81 99 68 70 132 132 122 142 136 144 118 120
38 32 M E 69 112 70 84 99 73 78 85 75 71 105 70 72 112 124 128 118 110 156 108 110
39 56 F E 70 126 84 98 100 76 79 90 95 88 98 74 76 126 136 130 142 131 140 120 122
40 44 F E 73 112 70 84 98 71 83 89 87 70 100 75 77 112 123 130 117 112 160 108 110
41 45 F E 88 140 86 104 100 88 97 90 98 91 92 78 70 126 118 124 138 130 130 134 128
42 48 F E 78 140 82 101 100 80 89 85 99 96 99 79 79 110 115 118 132 134 136 140 130
43 42 F E 86 132 81 97 98 85 94 90 105 109 100 86 87 124 126 120 146 140 141 142 132
44 40 M E 85 120 70 86 98 87 90 90 100 102 103 88 80 120 134 130 170 160 162 162 150
45 39 F E 83 110 70 83 99 80 89 85 90 95 99 80 80 118 118 122 138 142 144 146 140
46 45 M E 78 132 81 97 97 80 95 90 101 108 105 89 80 122 128 128 148 152 156 160 150
47 56 F E 75 116 68 84 97 78 87 85 97 98 98 88 80 134 127 130 149 145 140 127 130
48 33 F E 88 136 88 104 100 86 97 90 105 100 100 85 79 120 136 130 160 166 160 150 152
49 36 M E 79 120 70 86 96 85 90 89 98 88 88 72 74 120 128 136 178 166 154 136 114
50 39 M E 68 106 71 82 99 74 85 79 100 76 77 78 80 106 109 110 124 118 128 102 104
51 40 F E 76 132 78 95 99 82 100 95 104 96 98 76 78 132 138 142 154 141 138 136 128
52 49 F E 82 140 82 101 99 84 90 90 98 87 88 85 77 140 137 142 166 160 158 152 148
53 38 F E 75 142 84 103 100 79 93 85 92 86 87 65 67 142 142 150 158 131 130 127 129
54 32 F E 71 118 72 87 98 75 97 90 98 97 98 78 80 118 136 126 164 154 150 124 128
55 42 M E 78 128 82 97 98 84 100 90 110 107 107 90 87 128 127 132 154 150 146 142 132
56 33 M E 83 120 74 89 97 85 98 95 108 100 100 88 80 128 126 132 154 148 146 142 138
57 45 M E 79 113 60 83 100 80 98 90 102 105 106 99 84 130 122 132 152 148 150 150 148
58 38 M E 85 134 81 98 96 85 98 97 111 110 100 87 80 114 117 120 140 142 144 146 130
59 60 F E 84 116 68 84 100 86 94 93 99 95 97 85 87 122 136 148 166 170 166 152 146
60 44 F E 87 134 81 98 100 88 96 95 98 106 100 87 84 132 128 134 162 160 156 160 160
Sl.
No
DIASTOLIC ARTERIAL PRESSURE MEAN ATRERIAL PRESSURE O2 SATURATION Remarks
After
Drug
Admi
n
After
Induct
ion
After
Intub
ation
1
min
3
min
5
min
10
min
15
min
After
Drug
Admi
n
After
Induc
tion
After
Intub
ation
1
min
3
min
5
min
10
min
15
min
After
Drug
Admi
n
After
Induc
tion
After
Intub
ation
1
min
3
min
5
min
10
min
15
min
1 77 78 77 82 82 84 72 72 88 88 87 92 93 95 86 87 98 100 100 100 100 100 100 100 ACEI
2 82 82 80 86 84 86 86 82 98 91 90 99 98 100 101 99 99 100 100 100 100 100 100 100 ACEI
3 71 72 70 77 77 79 70 72 86 88 86 92 91 94 89 89 100 100 100 100 100 100 100 100 ACEI
4 72 75 71 72 74 77 74 70 87 89 84 87 89 91 90 87 100 100 100 100 100 100 100 100 DIURETICS
5 74 72 72 75 74 75 75 74 87 85 85 88 89 91 88 88 98 100 100 100 100 100 100 100 NONE
6 87 84 80 82 84 88 84 81 98 96 93 97 99 103 100 98 99 100 100 100 100 100 100 100 ACEI
7 92 90 90 92 94 92 94 92 108 109 107 109 109 107 109 109 100 100 100 100 100 100 100 100 β BLOCKER
8 81 80 80 82 84 86 83 82 97 97 97 99 101 101 99 97 100 100 100 100 100 100 100 100 β BLOCKER
9 82 83 80 82 82 80 78 80 97 99 95 100 98 97 97 99 100 100 100 100 100 100 100 100 β BLOCKER
10 84 82 82 80 84 82 82 84 97 95 95 95 99 99 99 98 98 100 100 100 100 100 100 100 β BLOCKER
11 61 62 60 64 71 72 68 69 74 74 73 79 84 85 83 83 97 100 100 100 100 100 100 100 ACEI
12 72 75 70 74 74 74 70 72 88 92 87 88 91 90 87 89 96 100 100 100 100 100 100 100 DIURETICS
13 61 60 60 62 66 66 60 62 79 79 80 85 88 88 84 85 95 100 100 100 100 100 100 100 NONE
14 62 60 61 64 67 68 67 62 77 73 74 78 81 82 82 78 100 100 100 100 100 100 100 100 NONE
15 77 75 77 79 78 78 77 77 88 87 87 93 94 93 92 93 100 100 100 100 100 100 100 100 β BLOCKER
16 75 78 78 76 80 80 82 80 85 86 86 87 90 90 91 89 100 100 100 100 100 100 100 100 β BLOCKER
17 80 80 77 82 83 83 85 79 97 97 95 100 99 99 102 96 98 100 100 100 100 100 100 100 ACEI
18 68 66 65 70 72 72 70 71 84 82 80 84 89 88 85 85 98 100 100 100 100 100 100 100 ACEI
19 83 80 80 85 86 88 86 82 96 90 90 96 97 99 97 94 99 100 100 100 100 100 100 100 β BLOCKER
20 67 65 65 68 70 72 70 71 79 77 77 82 84 86 85 84 97 100 100 100 100 100 100 100 DIURETICS
21 74 74 70 78 78 80 80 79 86 86 82 92 92 94 94 92 97 100 100 100 100 100 100 100 DIURETICS
22 90 92 90 90 92 90 92 90 103 105 101 104 105 103 105 104 100 100 100 100 100 100 100 100 NONE
23 76 101 80 112 100 112 90 88 89 115 97 121 115 121 100 98 100 100 100 100 100 100 100 100 ACEI
24 80 92 86 99 99 100 87 89 100 106 100 113 115 115 105 106 100 100 100 100 100 100 100 100 β BLOCKER
25 86 120 90 122 120 122 110 100 103 134 107 131 133 133 119 107 98 100 100 100 100 100 100 100 ACEI
26 80 90 88 102 96 98 90 88 98 111 102 118 112 113 102 102 99 100 100 100 100 100 100 100 ACEI
27 78 103 88 108 102 100 98 96 89 113 101 120 115 114 111 107 99 100 100 100 100 100 100 100 NONE
28 88 100 90 110 108 110 108 100 101 121 109 129 125 126 122 114 100 100 100 100 100 100 100 100 β BLOCKER
29 71 88 80 92 90 92 90 92 87 101 95 107 104 105 103 104 97 100 100 100 100 100 100 100 β BLOCKER
30 82 98 94 100 100 100 99 92 96 113 106 116 113 113 113 107 96 100 100 100 100 100 100 100 ACEI
31 62 76 76 90 90 92 88 78 78 90 91 108 110 112 109 99 100 100 100 100 100 100 100 100 NONE
32 70 72 80 90 86 88 78 82 88 89 99 109 111 113 89 93 100 100 100 100 100 100 100 100 β BLOCKER
33 79 87 88 88 72 98 72 82 91 100 100 100 82 109 82 89 100 100 100 100 100 100 100 100 β BLOCKER
34 90 95 80 100 92 90 82 95 107 108 93 117 105 105 101 110 96 100 100 100 100 100 100 100 ACEI
35 81 103 92 85 82 92 74 72 96 114 101 105 101 108 90 89 98 100 100 100 100 100 100 100 ACEI
36 78 98 92 92 91 108 70 72 88 107 105 107 102 126 83 85 99 100 100 100 100 100 100 100 ACEI
37 81 92 80 84 78 92 70 68 98 105 94 103 97 109 86 85 99 100 100 100 100 100 100 100 β BLOCKER
38 70 88 86 76 74 104 62 64 84 100 100 90 86 121 77 79 100 100 100 100 100 100 100 100 β BLOCKER
39 82 96 90 86 80 102 72 72 97 109 103 105 97 115 88 89 100 100 100 100 100 100 100 100 ACEI
40 68 80 88 69 70 114 60 68 83 94 102 85 84 129 76 82 99 100 100 100 100 100 100 100 ACEI
41 86 80 88 94 96 98 80 80 99 93 100 109 107 109 98 96 97 100 100 100 100 100 100 100 NONE
42 76 78 80 88 88 90 78 78 87 90 93 103 103 105 99 95 96 100 100 100 100 100 100 100 β BLOCKER
43 88 84 92 96 90 92 82 84 100 98 101 113 107 108 102 100 100 100 100 100 100 100 100 100 β BLOCKER
44 80 88 92 108 110 108 88 90 93 103 105 129 127 126 113 110 100 100 100 100 100 100 100 100 DIURETICS
45 70 80 80 94 91 92 80 89 86 93 94 109 108 109 102 106 99 100 100 100 100 100 100 100 NONE
46 78 84 86 100 102 104 92 94 93 99 100 116 119 121 115 113 96 100 100 100 100 100 100 100 ACEI
47 84 89 90 102 100 102 89 90 101 102 103 118 115 115 102 103 100 100 100 100 100 100 100 100 β BLOCKER
48 80 102 88 108 112 114 102 89 93 113 102 125 130 129 118 110 97 100 100 100 100 100 100 100 ACEI
49 70 96 99 110 104 106 90 64 87 107 111 133 125 122 105 81 98 100 100 100 100 100 100 100 DIURETICS
50 69 70 76 90 81 84 76 67 81 83 87 101 93 99 85 79 99 100 100 100 100 100 100 100 NONE
51 74 94 90 111 99 100 78 90 93 109 107 125 113 113 97 103 100 100 100 100 100 100 100 100 ACEI
52 71 86 90 110 104 102 90 89 94 103 107 129 123 121 111 109 100 100 100 100 100 100 100 100 β BLOCKER
53 84 94 98 112 105 106 92 96 103 110 115 127 114 114 104 107 100 100 100 100 100 100 100 100 ACEI
54 71 102 91 114 100 100 91 92 87 113 103 131 118 117 102 104 96 100 100 100 100 100 100 100 ACEI
55 82 90 90 101 93 92 101 93 97 102 104 119 112 110 115 106 99 100 100 100 100 100 100 100 NONE
56 86 80 82 98 98 99 88 90 100 95 99 117 115 115 106 106 98 100 100 100 100 100 100 100 β BLOCKER
57 70 82 82 96 96 98 80 89 90 95 99 115 113 115 103 109 99 100 100 100 100 100 100 100 β BLOCKER
58 70 70 80 92 90 92 84 88 85 86 93 108 107 109 105 102 100 100 100 100 100 100 100 100 DIURETICS
59 88 80 85 108 105 104 90 94 99 99 106 127 127 125 111 111 100 100 100 100 100 100 100 100 NONE
60 78 79 80 99 92 93 86 90 96 95 98 120 115 114 111 113 99 100 100 100 100 100 100 100 β BLOCKER
